AbbVie Inc. (NYSE:ABBV) Given Consensus Rating of “Moderate Buy” by Analysts

AbbVie Inc. (NYSE:ABBV) has been given a consensus recommendation of “Moderate Buy” by the twenty-three analysts that are currently covering the company, MarketBeat reports. Eight investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $249.3684.

ABBV has been the subject of several analyst reports. Bank of America upped their target price on AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Scotiabank started coverage on shares of AbbVie in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price objective for the company. JPMorgan Chase & Co. lifted their target price on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Monday, November 3rd. Erste Group Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating in a report on Tuesday, October 14th. Finally, Hsbc Global Res upgraded shares of AbbVie from a “hold” rating to a “strong-buy” rating in a report on Wednesday, December 10th.

Institutional Trading of AbbVie

Institutional investors and hedge funds have recently bought and sold shares of the stock. Almanack Investment Partners LLC. purchased a new stake in shares of AbbVie in the 4th quarter valued at approximately $276,000. Calamos Wealth Management LLC increased its holdings in AbbVie by 1.0% in the 4th quarter. Calamos Wealth Management LLC now owns 14,875 shares of the company’s stock valued at $3,399,000 after purchasing an additional 146 shares during the last quarter. Calamos Advisors LLC increased its holdings in AbbVie by 3.4% in the 4th quarter. Calamos Advisors LLC now owns 466,290 shares of the company’s stock valued at $106,543,000 after purchasing an additional 15,458 shares during the last quarter. ProVise Management Group LLC raised its position in AbbVie by 4.8% in the fourth quarter. ProVise Management Group LLC now owns 10,889 shares of the company’s stock valued at $2,488,000 after purchasing an additional 503 shares during the period. Finally, Obermeyer Wealth Partners lifted its stake in AbbVie by 1.0% during the fourth quarter. Obermeyer Wealth Partners now owns 10,606 shares of the company’s stock worth $2,423,000 after purchasing an additional 104 shares in the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Retrospective look: an analysis of why AbbVie outperformed in 2025 highlights management’s handling of blockbuster patent cliffs and portfolio transitions, supporting investor confidence in AbbVie’s strategy and cash returns. Why AbbVie Stock Trounced the Market in 2025
• Positive Sentiment: Berenberg raised its price target to $275 (from $270) and kept a Buy rating, citing momentum for Skyrizi and Rinvoq — a bullish signal from an institutional analyst that can support upside. Berenberg Grows More Confident in AbbVie
• Positive Sentiment: AbbVie and Novartis announced multi‑billion dollar licensing arrangements for oncology and Alzheimer’s treatments — a pipeline/collaboration boost that could add long-term revenue optionality. AbbVie and Novartis Announce Billion Dollar Licensing Deals
• Positive Sentiment: Clinical/dev updates: coverage discusses a bispecific trial win and AbbVie’s R&D commitments that could strengthen the growth narrative if results translate to approvals. Does AbbVie’s Bispecific Trial Win…
• Positive Sentiment: AbbVie completed a Phase 1 study for an on‑body injector to deliver risankizumab — operational progress that could improve dosing convenience and commercial uptake. AbbVie Advances Risankizumab Delivery
• Positive Sentiment: Allergan Aesthetics released pooled Phase 3 and Phase 4 data across injectables at IMCAS, underscoring strength in the aesthetics business line. Allergan Aesthetics Unveils New Data
• Positive Sentiment: On-air analyst support: a CNBC guest recommended staying long AbbVie, a short-term endorsement that can help sentiment. AbbVie on CNBC’s ‘Final Trades’
• Neutral Sentiment: Options activity: commentary notes unusual options movement, worth watching for short-term volatility but not definitive direction. Is the Options Market Predicting a Spike?
• Neutral Sentiment: Insider/holder note: a small asset manager disclosed a modest stake increase — a minor vote of confidence but immaterial to market cap. Belpointe Asset Management Increases Stake
• Neutral Sentiment: Corporate philanthropy: the AbbVie Foundation opened applications for a health equity accelerator — positive PR but unlikely to move the stock. AbbVie Foundation Health Equity Accelerator
• Negative Sentiment: Policy risk: CMS named several AbbVie drugs for the third cycle of Medicare Drug Price Negotiations — a direct potential headwind to pricing and margins if negotiations lower reimbursement. US Medicare names Eli Lilly, Pfizer and AbbVie drugs
• Negative Sentiment: Earnings outlook: a Zacks preview said AbbVie lacks the setup for a clear earnings beat next week — a factor that can pressure near-term multiple and stock momentum. AbbVie Reports Next Week
• Negative Sentiment: Analyst change: Citigroup trimmed its price target to $230 and moved to Neutral, signaling less near-term upside from analyst coverage. Citigroup Lowers Price Target

AbbVie Trading Down 2.2%

ABBV stock opened at $218.99 on Thursday. The firm has a 50-day moving average of $224.85 and a two-hundred day moving average of $218.01. AbbVie has a 12 month low of $164.39 and a 12 month high of $244.81. The company has a market cap of $387.04 billion, a price-to-earnings ratio of 165.90, a PEG ratio of 0.92 and a beta of 0.36.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. During the same period in the prior year, the business earned $3.00 earnings per share. The business’s revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities analysts forecast that AbbVie will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a $1.73 dividend. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a yield of 3.2%. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio (DPR) is presently 524.24%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.